Corcept Therapeutics (CORT) Tops Q3 EPS by 5c; Reaffirms

Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.22, $0.05 better than the analyst estimate of $0.17. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67.41 million.

GUIDANCE:

Reaffirmed 2018 revenue guidance of $250-270 million

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes